SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001389933-17-000010
Filing Date
2017-02-14
Accepted
2017-02-14 13:24:51
Documents
1
Group Members
NATHAN FISCHEL, FARIBA GHODSIAN

Document Format Files

Seq Description Document Type Size
1 dafna13gsnss2016.txt SC 13G 10048
  Complete submission text file 0001389933-17-000010.txt   11719
Mailing Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080 650-266-3500
SUNESIS PHARMACEUTICALS INC (Subject) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-81034 | Film No.: 17606374
SIC: 2834 Pharmaceutical Preparations

Mailing Address 10990 WILSHIRE BOULEVARD SUITE 1400 LOS ANGELES CA 90024
Business Address 10990 WILSHIRE BOULEVARD SUITE 1400 LOS ANGELES CA 90024 (310) 954-3200
DAFNA Capital Management LLC (Filed by) CIK: 0001389933 (see all company filings)

IRS No.: 364334068
Type: SC 13G